Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis

Yu Jeong Kim; Su Young Chae; Cheng Hao Jin; M. Sivasubramanian; Sohee Son; Ki Young Choi; Dong Gyu Jo; Kwangmeyung Kim; Ick Chan Kwon; Kang Choon Lee; Jae Hyung Park

doi:10.1016/j.biomaterials.2010.08.015

Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis

Yu Jeong Kim, Su Young Chae, Cheng Hao Jin, M. Sivasubramanian, Sohee Son, Ki Young Choi, Dong Gyu Jo, Kwangmeyung Kim, Ick Chan Kwon, Kang Choon Lee, Jae Hyung Park

Department of Pharmaceutical Sciences

Research output: Contribution to journal › Article › peer-review

59 Scopus citations

Abstract

The clinical applications of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), an emerging therapeutic protein for cancer and rheumatoid arthritis (RA), are limited by its instability and short biological half-life. In this study, efficient therapeutic modalities for RA treatment were developed in the form of nano-sized complexes (nanocomplexes) based on hyaluronic acid (HA) and polyethylene glycol (PEG)-derivatized TRAIL (PEG-TRAIL) formed by N-terminal specific PEGylation. The nanocomplexes were prepared by simply mixing the positively charged PEG-TRAIL and negatively charged HA, and showed negligible loss of bioactivity compared with the PEG-TRAIL. The in vivo biodistribution and diffusion kinetics of Cy5.5-labeled PEG-TRAIL in mice were observed using a near-infrared optical imaging system after subcutaneous injection of three different formulations: PEG-TRAIL in phosphate-buffered saline (PBS, pH 7.4), nanocomplex in PBS, or nanocomplex in 1% HA solution. The results suggested that PEG-TRAIL is released slowly in vivo from the nanocomplex in 1% HA. Experiments in a collagen-induced arthritis mouse model demonstrated that the magnitudes of therapeutic effects, as judged by clinical scores and histology, were significantly enhanced by the sustained delivery of PEG-TRAIL, with the order of nanocomplex in 1% HA > nanocomplex in PBS > PEG-TRAIL in PBS. In addition, sustained delivery of PEG-TRAIL from the nanocomplex in 1% HA resulted in significant reduction of serum inflammatory cytokines and collagen-specific antibodies that are responsible for the pathogenesis of RA. These results imply that HA/PEG-TRAIL nanocomplex formulations are promising therapeutic modalities for the treatment of RA.

Original language	English
Pages (from-to)	9057-9064
Number of pages	8
Journal	Biomaterials
Volume	31
Issue number	34
DOIs	https://doi.org/10.1016/j.biomaterials.2010.08.015
State	Published - Dec 2010

Bibliographical note

Funding Information:
This work was supported by the Ministry of Education, Science and Technology (20090081871 and 20100015804), the National R&D Program for Cancer Control (0920120) and the Korea Health 21 R&D Project (A062254) of MIHWAF, and BioImaging Research Center at GIST, Republic of Korea.

Keywords

Hyaluronic acid
Nanocomplex
PEG-TRAIL
Protein delivery
Rheumatoid arthritis

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.biomaterials.2010.08.015

Cite this

Kim, Y. J., Chae, S. Y., Jin, C. H., Sivasubramanian, M., Son, S., Choi, K. Y., Jo, D. G., Kim, K., Chan Kwon, I., Lee, K. C., & Park, J. H. (2010). Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis. Biomaterials, 31(34), 9057-9064. https://doi.org/10.1016/j.biomaterials.2010.08.015

@article{8474309bef034e51aa9a0a817cc60831,

title = "Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis",

abstract = "The clinical applications of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), an emerging therapeutic protein for cancer and rheumatoid arthritis (RA), are limited by its instability and short biological half-life. In this study, efficient therapeutic modalities for RA treatment were developed in the form of nano-sized complexes (nanocomplexes) based on hyaluronic acid (HA) and polyethylene glycol (PEG)-derivatized TRAIL (PEG-TRAIL) formed by N-terminal specific PEGylation. The nanocomplexes were prepared by simply mixing the positively charged PEG-TRAIL and negatively charged HA, and showed negligible loss of bioactivity compared with the PEG-TRAIL. The in vivo biodistribution and diffusion kinetics of Cy5.5-labeled PEG-TRAIL in mice were observed using a near-infrared optical imaging system after subcutaneous injection of three different formulations: PEG-TRAIL in phosphate-buffered saline (PBS, pH 7.4), nanocomplex in PBS, or nanocomplex in 1% HA solution. The results suggested that PEG-TRAIL is released slowly in vivo from the nanocomplex in 1% HA. Experiments in a collagen-induced arthritis mouse model demonstrated that the magnitudes of therapeutic effects, as judged by clinical scores and histology, were significantly enhanced by the sustained delivery of PEG-TRAIL, with the order of nanocomplex in 1% HA > nanocomplex in PBS > PEG-TRAIL in PBS. In addition, sustained delivery of PEG-TRAIL from the nanocomplex in 1% HA resulted in significant reduction of serum inflammatory cytokines and collagen-specific antibodies that are responsible for the pathogenesis of RA. These results imply that HA/PEG-TRAIL nanocomplex formulations are promising therapeutic modalities for the treatment of RA.",

keywords = "Hyaluronic acid, Nanocomplex, PEG-TRAIL, Protein delivery, Rheumatoid arthritis",

author = "Kim, {Yu Jeong} and Chae, {Su Young} and Jin, {Cheng Hao} and M. Sivasubramanian and Sohee Son and Choi, {Ki Young} and Jo, {Dong Gyu} and Kwangmeyung Kim and {Chan Kwon}, Ick and Lee, {Kang Choon} and Park, {Jae Hyung}",

note = "Funding Information: This work was supported by the Ministry of Education, Science and Technology (20090081871 and 20100015804), the National R&D Program for Cancer Control (0920120) and the Korea Health 21 R&D Project (A062254) of MIHWAF, and BioImaging Research Center at GIST, Republic of Korea. ",

year = "2010",

month = dec,

doi = "10.1016/j.biomaterials.2010.08.015",

language = "English",

volume = "31",

pages = "9057--9064",

journal = "Biomaterials",

issn = "0142-9612",

publisher = "Elsevier BV",

number = "34",

}

TY - JOUR

T1 - Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis

AU - Kim, Yu Jeong

AU - Chae, Su Young

AU - Jin, Cheng Hao

AU - Sivasubramanian, M.

AU - Son, Sohee

AU - Choi, Ki Young

AU - Jo, Dong Gyu

AU - Kim, Kwangmeyung

AU - Chan Kwon, Ick

AU - Lee, Kang Choon

AU - Park, Jae Hyung

N1 - Funding Information: This work was supported by the Ministry of Education, Science and Technology (20090081871 and 20100015804), the National R&D Program for Cancer Control (0920120) and the Korea Health 21 R&D Project (A062254) of MIHWAF, and BioImaging Research Center at GIST, Republic of Korea.

PY - 2010/12

Y1 - 2010/12

N2 - The clinical applications of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), an emerging therapeutic protein for cancer and rheumatoid arthritis (RA), are limited by its instability and short biological half-life. In this study, efficient therapeutic modalities for RA treatment were developed in the form of nano-sized complexes (nanocomplexes) based on hyaluronic acid (HA) and polyethylene glycol (PEG)-derivatized TRAIL (PEG-TRAIL) formed by N-terminal specific PEGylation. The nanocomplexes were prepared by simply mixing the positively charged PEG-TRAIL and negatively charged HA, and showed negligible loss of bioactivity compared with the PEG-TRAIL. The in vivo biodistribution and diffusion kinetics of Cy5.5-labeled PEG-TRAIL in mice were observed using a near-infrared optical imaging system after subcutaneous injection of three different formulations: PEG-TRAIL in phosphate-buffered saline (PBS, pH 7.4), nanocomplex in PBS, or nanocomplex in 1% HA solution. The results suggested that PEG-TRAIL is released slowly in vivo from the nanocomplex in 1% HA. Experiments in a collagen-induced arthritis mouse model demonstrated that the magnitudes of therapeutic effects, as judged by clinical scores and histology, were significantly enhanced by the sustained delivery of PEG-TRAIL, with the order of nanocomplex in 1% HA > nanocomplex in PBS > PEG-TRAIL in PBS. In addition, sustained delivery of PEG-TRAIL from the nanocomplex in 1% HA resulted in significant reduction of serum inflammatory cytokines and collagen-specific antibodies that are responsible for the pathogenesis of RA. These results imply that HA/PEG-TRAIL nanocomplex formulations are promising therapeutic modalities for the treatment of RA.

AB - The clinical applications of tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL), an emerging therapeutic protein for cancer and rheumatoid arthritis (RA), are limited by its instability and short biological half-life. In this study, efficient therapeutic modalities for RA treatment were developed in the form of nano-sized complexes (nanocomplexes) based on hyaluronic acid (HA) and polyethylene glycol (PEG)-derivatized TRAIL (PEG-TRAIL) formed by N-terminal specific PEGylation. The nanocomplexes were prepared by simply mixing the positively charged PEG-TRAIL and negatively charged HA, and showed negligible loss of bioactivity compared with the PEG-TRAIL. The in vivo biodistribution and diffusion kinetics of Cy5.5-labeled PEG-TRAIL in mice were observed using a near-infrared optical imaging system after subcutaneous injection of three different formulations: PEG-TRAIL in phosphate-buffered saline (PBS, pH 7.4), nanocomplex in PBS, or nanocomplex in 1% HA solution. The results suggested that PEG-TRAIL is released slowly in vivo from the nanocomplex in 1% HA. Experiments in a collagen-induced arthritis mouse model demonstrated that the magnitudes of therapeutic effects, as judged by clinical scores and histology, were significantly enhanced by the sustained delivery of PEG-TRAIL, with the order of nanocomplex in 1% HA > nanocomplex in PBS > PEG-TRAIL in PBS. In addition, sustained delivery of PEG-TRAIL from the nanocomplex in 1% HA resulted in significant reduction of serum inflammatory cytokines and collagen-specific antibodies that are responsible for the pathogenesis of RA. These results imply that HA/PEG-TRAIL nanocomplex formulations are promising therapeutic modalities for the treatment of RA.

KW - Hyaluronic acid

KW - Nanocomplex

KW - PEG-TRAIL

KW - Protein delivery

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=77957313563&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2010.08.015

DO - 10.1016/j.biomaterials.2010.08.015

M3 - Article

C2 - 20813405

AN - SCOPUS:77957313563

SN - 0142-9612

VL - 31

SP - 9057

EP - 9064

JO - Biomaterials

JF - Biomaterials

IS - 34

ER -

Ionic complex systems based on hyaluronic acid and PEGylated TNF-related apoptosis-inducing ligand for treatment of rheumatoid arthritis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this